The Curbsiders Internal Medicine Podcast cover image

#396 Recap, Top Pearls from #SGIM23

The Curbsiders Internal Medicine Podcast

00:00

The Clarity AD Trial

The Clarity AD trial evaluated the new monoclonal antibody, Lacanamab. It is great at reducing soluble amyloid. The bad news is that clinically, the reduction in function does not mitigate that much. But there were some pretty significant adverse events, including the death.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app